Hepatitis D Market to Expand Significantly by 2034, States DelveInsight Report | Gilead Sciences, Eiger BioPharma, Janssen R&D

The Key Hepatitis D Companies in the market include - Gilead Sciences, Eiger BioPharmaceuticals, Janssen Research & Development, and others.

The Hepatitis D market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatitis D pipeline products will significantly revolutionize the Hepatitis D market dynamics.

DelveInsight's "Hepatitis D Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hepatitis D, historical and forecasted epidemiology as well as the Hepatitis D market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hepatitis D market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Hepatitis D market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatitis D Market Forecast [https://www.delveinsight.com/sample-request/hepatitis-d-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Hepatitis D Market Report:

*
The Hepatitis D market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In December 2024, Tobevibart and elebsiran, an investigational treatment combination developed by Vir Biotechnology for chronic hepatitis D, has received both Breakthrough Therapy Designation from the U.S. FDA and Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA). These designations aim to accelerate the development and review of promising therapies that address unmet medical needs and provide potential advantages over existing treatment options.

*
In November 2024, Following encouraging results from its Phase 2 clinical trial, Vir Biotechnology is preparing to launch its Phase 3 ECLIPSE program in 2025 to evaluate the combination of tobevibart and elebsiran in adults with chronic hepatitis D. If successful, the findings from the two Phase 3 trials could support regulatory approval applications for the treatment. Data from the ongoing Phase 2 SOLSTICE study (NCT05461170) indicate that the combination therapy effectively suppressed the hepatitis delta virus (HDV) and helped normalize a liver damage marker in patients with hepatitis D.

*
In September 2023, Eiger BioPharmaceuticals decided to halt the Phase III LIMT-2 study evaluating peginterferon lambda in chronic hepatitis D patients. This decision follows a quarterly safety review by the Data Safety Monitoring Board (DSMB), which recommended discontinuation.

*
In the 7MM, the United States recorded the highest number of diagnosed prevalent cases of Hepatitis D virus in 2023.

*
In the U.S., males had a higher number of diagnosed prevalent cases of Hepatitis D compared to females in 2023.

*
In the U.S., the 18-34 age group had the highest number of diagnosed cases of Hepatitis D in 2023.

*
In the U.S., the 18-34 age group had the highest number of diagnosed cases of Hepatitis D in 2023.

*
Key Hepatitis D Companies: Gilead Sciences, Eiger BioPharmaceuticals, Janssen Research & Development, and others

*
Key Hepatitis D Therapies: HEPCLUDEX (bulevirtide), Lonafarnib; Peginterferon Lambda-1a, JNJ-3989, and others

*
The Hepatitis D epidemiology based on gender analyzed that Hepatitis D is more prevalent in males as compared to females

Hepatitis D Overview

Hepatitis D (HDV) is a rare but severe liver infection caused by the hepatitis D virus. It occurs only in individuals already infected with hepatitis B (HBV), as HDV requires HBV to replicate. The infection can lead to rapid liver damage, increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma. Transmission occurs through contact with infected blood or bodily fluids, often via injection drug use. Currently, no specific antiviral treatment is widely available, but HBV vaccination can help prevent Hepatitis D by preventing HBV infection.

Get a Free sample for the Hepatitis D Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/hepatitis-d-market [https://www.delveinsight.com/report-store/hepatitis-d-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hepatitis D Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hepatitis D Epidemiology Segmentation:

The Hepatitis D market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Hepatitis D

*
Prevalent Cases of Hepatitis D by severity

*
Gender-specific Prevalence of Hepatitis D

*
Diagnosed Cases of Episodic and Chronic Hepatitis D

Download the report to understand which factors are driving Hepatitis D epidemiology trends @ Hepatitis D Epidemiological Insights [https://www.delveinsight.com/sample-request/hepatitis-d-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hepatitis D Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis D market or expected to get launched during the study period. The analysis covers Hepatitis D market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hepatitis D Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hepatitis D Therapies and Key Companies

*
HEPCLUDEX (Bulevirtide): Gilead Sciences

*
Lonafarnib/ Ritonavir: Eiger Biopharmaceuticals

*
JNJ-73763989: Johnson & Johnson

To know more about Hepatitis D treatment, visit @ Hepatitis D Medications [https://www.delveinsight.com/sample-request/hepatitis-d-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hepatitis D Market Drivers

*
Opioid epidemic causes increase in new Hepatitis B Virus - Hepatitis D infections because of injection drug use and needle sharing

*
Globally, Hepatitis D infection is reported to be present in approximately 4% to 6% of chronic hepatitis B carriers and the new epidemiology studies suggested that up to 70 million people worldwide may be infected with Hepatitis D

Hepatitis D Market Barriers

*
Lack of standardization in Hepatitis D testing

*
Lack of awareness of Hepatitis D

*
Impact of Hepatitis B Virus / Hepatitis D in progression to cirrhosis

*
Need of long-lasting and sustained delivery formulations

Scope of the Hepatitis D Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Hepatitis D Companies: Gilead Sciences, Eiger BioPharmaceuticals, Janssen Research & Development, and others

*
Key Hepatitis D Therapies: HEPCLUDEX (bulevirtide), Lonafarnib; Peginterferon Lambda-1a, JNJ-3989, and others

*
Hepatitis D Therapeutic Assessment: Hepatitis D current marketed and Hepatitis D emerging therapies

*
Hepatitis D Market Dynamics: Hepatitis D market drivers and Hepatitis D market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Hepatitis D Unmet Needs, KOL's views, Analyst's views, Hepatitis D Market Access and Reimbursement

Discover more about therapies set to grab major Hepatitis D market share @ Hepatitis D Treatment Landscape [https://www.delveinsight.com/sample-request/hepatitis-d-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hepatitis D Market Report Introduction

2. Executive Summary for Hepatitis D

3. SWOT analysis of Hepatitis D

4. Hepatitis D Patient Share (%) Overview at a Glance

5. Hepatitis D Market Overview at a Glance

6. Hepatitis D Disease Background and Overview

7. Hepatitis D Epidemiology and Patient Population

8. Country-Specific Patient Population of Hepatitis D

9. Hepatitis D Current Treatment and Medical Practices

10. Hepatitis D Unmet Needs

11. Hepatitis D Emerging Therapies

12. Hepatitis D Market Outlook

13. Country-Wise Hepatitis D Market Analysis (2020-2034)

14. Hepatitis D Market Access and Reimbursement of Therapies

15. Hepatitis D Market Drivers

16. Hepatitis D Market Barriers

17. Hepatitis D Appendix

18. Hepatitis D Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatitis-d-market-to-expand-significantly-by-2034-states-delveinsight-report-gilead-sciences-eiger-biopharma-janssen-rd]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.